Associated Papers
Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia.
Liu Y et al.
Heliyon, 2024
38831838 (PubMed )
Supplement: mmc3.xlsx › Sheet1
Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis.
Uddin MM et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
37732181 (PubMed )
Supplement: media-2.xlsx › Table_S3
Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome.
Jung HA et al.
The Korean Journal of Internal Medicine, 2021
TET2 missense variants in human neoplasia. A proposal of structural and functional classification.
Bussaglia E et al.
Molecular Genetics & Genomic Medicine, 2019
31187595 (PubMed )
Supplement: MGG3-7-e00772-s004.doc
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.
Wong TN et al.
Nature Communications, 2018
29386642 (PubMed )
Supplement: 41467_2018_2858_MOESM5_ESM.xlsx › Sheet1
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.
Palomero T et al.
Nature Genetics, 2014
24413734 (PubMed )
Supplement: NIHMS549899-supplement-2.xlsx › Supplementary_Table_5
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2012
22430270 (PubMed )
Supplement: 392886_Gaidzik_DataSupp_revised.pdf
Select a paper to view details